Acrodermatitis Chronica Atrophicans Medication
- Author: Bozena Chodynicka, MD; Chief Editor: Dirk M Elston, MD more...
Medication Summary
The goals of pharmacotherapy are to eradicate the infection, to reduce morbidity, and to prevent complications. Various antibiotics are used to treat acrodermatitis chronica atrophicans (ACA).
Antibiotics
Class Summary
Empiric antimicrobial therapy for ACA must be comprehensive and should cover all pathogens likely to be present in the context of this clinical setting.
Amoxicillin (Moxatag)
Amoxicillin is bactericidal against Borrelia species. It is a semisynthetic penicillin of the aminopenicillin group that demonstrates a wide spectrum of bactericidal activity related to gram-positive and gram-negative bacteria. Its mechanism of action involves inhibition of
Doxycycline (Vibramycin, Adoxa, Doryx, Monodox)
Doxycycline is a tetracycline antibiotic that inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. It is used for its antibacterial and anti-inflammatory effect and may be considered when there is concern about possible coexistent infection.
Ceftriaxone (Rocephin)
Ceftriaxone is bactericidal against Borrelia species. It is a third-generation cephalosporin with broad-spectrum gram-negative activity. Ceftriaxone has lower efficacy against gram-positive organisms and higher efficacy against resistant organisms. It arrests bacterial growth by binding to 1 or more penicillin-binding proteins.
Cefotaxime (Claforan)
Cefotaxime is a third-generation semisynthetic cephalosporin with broad-spectrum bactericidal activity against gram-negative bacteria and Staphylococcus and Streptococcus species. It is resistant to beta-lactamases. Its mechanism of action is related to inhibition of bacteria cell wall synthesis.
Penicillin G (Pfizerpen)
Penicillin G is a beta-lactam antibiotic. Its mechanism of action is related to inhibition of bacterial cell wall synthesis in the growth phase as a result of penicillin and bacterial transpeptidase binding.
Bhate C, Schwartz RA. Lyme disease: Part I. Advances and perspectives. J Am Acad Dermatol. Apr 2011;64(4):619-36; quiz 637-8. [Medline].
Bhate C, Schwartz RA. Lyme disease: Part II. Management and prevention. J Am Acad Dermatol. Apr 2011;64(4):639-53; quiz 654, 653. [Medline].
Buchwald A. Ein Fall von diffuser idiopathischer Haut-Atrophie. Vrtljschr Derm. 1883;10:553-6.
Herxheimer K, Hartmann K. Ueber Acrodermatitis chronica atrophicans. Arch f Dermatol u Syph (Wien). 1902;61:57-76.
Smetanick MT, Zellis SL, Ermolovich T. Acrodermatitis chronica atrophicans: a case report and review of the literature. Cutis. May 2010;85(5):247-52. [Medline].
Aberer E. Country report - Austria. Report of WHO Workshop on Lyme Borreliosis Diagnosis and Surveillance, Warsaw. Warsaw, Poland: World Health Organization; 1995.
Christova I, Komitova R. Clinical and epidemiological features of Lyme borreliosis in Bulgaria. Wien Klin Wochenschr. Jan 31 2004;116(1-2):42-6. [Medline].
Flisiak I, Schwartz RA, Chodynicka B. Clinical features and specific immunological response to Borrelia afzelii in patients with acrodermatitis chronica atrophicans. J Med. 1999;30(3-4):267-78. [Medline].
Zalaudek I, Leinweber B, Kerl H, Mullegger RR. Acrodermatitis chronica atrophicans in a 15-year-old girl misdiagnosed as venous insufficiency for 6 years. J Am Acad Dermatol. 2005;52:1091-4. [Medline].
Andres C, Ziai M, Bruckbauer H, Ring J, Hofmann H. Acrodermatitis chronica atrophicans in two children. Int J Dermatol. Feb 2010;49(2):180-3. [Medline].
Leverkus M, Finner AM, Pokrywka A, Franke I, Gollnick H. Metastatic squamous cell carcinoma of the ankle in long-standing untreated acrodermatitis chronica atrophicans. Dermatology. 2008;217(3):215-8. [Medline].
Danz B, Kreft B, Radant K, Marsch WCh, Fiedler E. Skin-coloured facial oedema as an initial manifestation of acrodermatitis chronica atrophicans. J Eur Acad Dermatol Venereol. Jun 2008;22(6):751-3. [Medline].
Mullegger RR, Glatz M. Skin manifestations of lyme borreliosis: diagnosis and management. Am J Clin Dermatol. 2008;9(6):355-68. [Medline].
Maraspin V, Ogrinc K, Ružic-Sabljic E, Lotric-Furlan S, Strle F. Isolation of Borrelia burgdorferi sensu lato from blood of adult patients with borrelial lymphocytoma, Lyme neuroborreliosis, Lyme arthritis and acrodermatitis chronica atrophicans. Infection. Feb 2011;39(1):35-40. [Medline].

